Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accumulated Expenses (2020 - 2024)

Historic Accumulated Expenses for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • Burning Rock Biotech's Accumulated Expenses fell 1934.98% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 1934.98%. This contributed to the annual value of $12.3 million for FY2024, which is 1703.65% down from last year.
  • Per Burning Rock Biotech's latest filing, its Accumulated Expenses stood at $10.8 million for Q3 2025, which was down 1934.98% from $10.5 million recorded in Q2 2025.
  • Over the past 5 years, Burning Rock Biotech's Accumulated Expenses peaked at $90.0 million during Q4 2021, and registered a low of $9.2 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $13.4 million (2024), whereas its average is $18.3 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Accumulated Expenses soared by 60184.09% in 2021, and later crashed by 7198.92% in 2022.
  • Over the past 5 years, Burning Rock Biotech's Accumulated Expenses (Quarter) stood at $90.0 million in 2021, then crashed by 71.99% to $25.2 million in 2022, then tumbled by 41.36% to $14.8 million in 2023, then decreased by 17.04% to $12.3 million in 2024, then dropped by 11.79% to $10.8 million in 2025.
  • Its Accumulated Expenses stands at $10.8 million for Q3 2025, versus $10.5 million for Q2 2025 and $10.5 million for Q1 2025.